We’re on a mission

Our world-class scientific team brings together leading experts in oncology, immunology, machine learning, virology and even theoretical physics.

We have partnerships with top academic labs at the cutting edge of research in essential fields including viral mimicry, crystallography and computational biology.

We are proud to be backed by an outstanding group of investors and guided by a board with deep expertise in building successful biotech companies.

Our name pays homage to the spirit of exploration and innovation in ancient Rome — and it’s also a fun play on the word “repeatome.” The “O” in our logo is designed as a toggle switch, reflecting our ambition to illuminate the secrets of this uncharted territory.

A dedicated team

Management Team

ROSANA KAPELLER, M.D., Ph.D. ROSANA KAPELLER, M.D., Ph.D.
As a “carioca” (meaning a native of Rio De Janiero), Rosana loves to dance the samba.
ROSANA KAPELLER, M.D., Ph.D.
Co-founder, President and CEO

A champion of exploring new frontiers who brings deep expertise in machine learning and computational technologies and extensive experience in company formation, drug discovery and development.

DENNIS ZALLER, Ph.D.
Chief Scientific Officer

A highly experienced drug discovery scientist and immunology expert with a successful track record of developing innovative medicines for patients in need across multiple therapeutic areas, including cancer and autoimmune disease.

DENNIS ZALLER, Ph.D. DENNIS ZALLER, Ph.D.
Dennis enjoys swimming in cold mountain lakes and body surfing in warm ocean waters.
DENNIS ZALLER, Ph.D.
Chief Scientific Officer

A highly experienced drug discovery scientist and immunology expert with a successful track record of developing innovative medicines for patients in need across multiple therapeutic areas, including cancer and autoimmune disease.

CHRISTINE LOGGINS CHRISTINE LOGGINS
One of Christine's hidden talents: walking on stilts, which she learned to do for a high school play. 
CHRISTINE LOGGINS
Senior Vice President, Strategy and Operations

A business leader passionate about translating science into strategy, with broad experience in operations, M&A and communications across hematology and oncology.

DONNA ROMERO, Ph.D.
Senior Vice President, Chemistry

A veteran chemist with extensive leadership experience who is fluent in medicinal, computational and synthetic chemistry.

DONNA ROMERO, Ph.D. DONNA ROMERO, Ph.D.
Donna played Division III tennis at Emory University.
DONNA ROMERO, Ph.D.
Senior Vice President, Chemistry

A veteran chemist with extensive leadership experience who is fluent in medicinal, computational and synthetic chemistry.

KIRA NELSON KIRA NELSON
In her down time, Kira loves to golf with family and is an avid reader.
KIRA NELSON
Vice President, Finance

A longtime biotech executive who brings a sharp focus on finance, operations and strategic planning.

WENYAN MIAO, Ph.D.
Vice President, Biology and Preclinical Development

A scientific leader with an excellent track record in leading both protein therapeutics and small molecule projects from target research to early clinical studies.

WENYAN MIAO, Ph.D. WENYAN MIAO, Ph.D.
In Wenyan's time off, she loves watching animated movies; her favorites are Madagascar and Surf’s Up!
WENYAN MIAO, Ph.D.
Vice President, Biology and Preclinical Development

A scientific leader with an excellent track record in leading both protein therapeutics and small molecule projects from target research to early clinical studies.

DAVID PROIA, Ph.D. DAVID PROIA, Ph.D.
David enjoys long distance running and has completed three marathons, including the 2014 Boston Marathon.
DAVID PROIA, Ph.D.
Vice President, Oncology

A veteran biologist and pharmacologist with a successful track record of discovering and developing new oncology therapeutics from concept through IND and late-stage clinical studies.

MENACHEM FROMER, Ph.D.
Head of Data Science

A leading computer scientist, genomics researcher, and machine learning scientist who has applied innovative models to characterize the behaviors and genetics of psychiatric disorders.

MENACHEM FROMER, Ph.D. MENACHEM FROMER, Ph.D.
Menachem is all about adventure and loves ziplining, jet skiing and paragliding.
MENACHEM FROMER, Ph.D.
Head of Data Science

A leading computer scientist, genomics researcher, and machine learning scientist who has applied innovative models to characterize the behaviors and genetics of psychiatric disorders.

Board of Directors

SCOTT BILLER, Ph.D.
SCOTT BILLER, Ph.D.
Strategic Advisor, Agios Pharmaceuticals

Scott Biller, PhD, is a strategic advisor to Agios Pharmaceuticals and served as the Company’s Chief Scientific Officer from 2010-2019. During his tenure as CSO at Agios, Scott advanced seven molecules into the clinic that resulted in two marketed therapies and multiple late-stage candidates.

 

More
KRISTINA BUROW
Managing Director, ARCH Venture Partners

A company creator who has played a major role in founding and launching multiple high-performing companies with backing from ARCH Venture Partners.

More
KRISTINA BUROW
KRISTINA BUROW
Managing Director, ARCH Venture Partners

A company creator who has played a major role in founding and launching multiple high-performing companies with backing from ARCH Venture Partners.

More
STEVEN J. KAFKA, Ph.D.
STEVEN J. KAFKA, Ph.D.
Managing Partner, Section 32

Steve works with exceptional scientists and entrepreneurs to help build companies that seek to create vast improvements in patient care and rewarding professional opportunities for employees.

More
ROSANA KAPELLER, M.D., Ph.D.
Co-founder, President and CEO, ROME Therapeutics

A champion of exploring new frontiers who brings deep expertise in machine learning and computational technologies and extensive experience in company formation, drug discovery and development.

More
ROSANA KAPELLER, M.D., Ph.D.
ROSANA KAPELLER, M.D., Ph.D.
Co-founder, President and CEO, ROME Therapeutics

A champion of exploring new frontiers who brings deep expertise in machine learning and computational technologies and extensive experience in company formation, drug discovery and development.

More
JEB KEIPER
JEB KEIPER
CEO, Nimbus Therapeutics

A chemist by training who has decades of leadership experience in business development and business strategy, with a long-standing focus on oncology.

More
JAY PARRISH, Ph.D.
Chairman, Pretzel Therapeutics and Venture Partner, ARCH Ventures

Jay Parrish is Chairman of Pretzel Therapeutics, a Venture Partner at ARCH Venture Partners and co-founder of ROME Therapeutics.

More
JAY PARRISH, Ph.D.
JAY PARRISH, Ph.D.
Chairman, Pretzel Therapeutics and Venture Partner, ARCH Ventures

Jay Parrish is Chairman of Pretzel Therapeutics, a Venture Partner at ARCH Venture Partners and co-founder of ROME Therapeutics.

More
JIM TRENKLE, Ph.D.
JIM TRENKLE, Ph.D.
Head of investments, Sanofi Ventures

An investor-scientist with experience in medicinal chemistry, drug development, and commercialization.

More
KRISHNA YESHWANT, M.D.
General Partner, GV

A physician, programmer and entrepreneur who brings a broad perspective across all aspects of the biotech industry as a general partner at GV.

More
KRISHNA YESHWANT, M.D.
KRISHNA YESHWANT, M.D.
General Partner, GV

A physician, programmer and entrepreneur who brings a broad perspective across all aspects of the biotech industry as a general partner at GV.

More

Scientific Co-founders

DAVID TING, M.D. DAVID TING, M.D.
David was a chef for his house at MIT, cooking "high throughput" meals for 53 hungry guys each week
DAVID TING, M.D.
Associate Clinical Director for Innovation, Massachusetts General Hospital Cancer Center

A physician scientist, cancer biologist and bioengineer who serves as associate clinical director for innovation at the Massachusetts General Hospital Cancer Center.

BENJAMIN GREENBAUM, Ph.D.
Memorial Sloan Kettering Cancer Center

A theoretical physicist by training who studies the intersection of cancer research, immunology, evolutionary theory and virology.

BENJAMIN GREENBAUM, Ph.D. BENJAMIN GREENBAUM, Ph.D.
A high school public speaking champion who won back-to-back state titles in Florida, Ben confesses to an extreme weakness for sweets
BENJAMIN GREENBAUM, Ph.D.
Memorial Sloan Kettering Cancer Center

A theoretical physicist by training who studies the intersection of cancer research, immunology, evolutionary theory and virology.

Scientific Advisory Board

EDDY ARNOLD, Ph.D.
Board of Governors and Distinguished Professor, Rutgers University

A renowned chemist who helped pioneer understanding of the HIV reverse transcriptase to develop a novel class of AIDS drugs.

More
NINA BHARDWAJ, M.D., Ph.D.
Director of Immunotherapy, Vaccine and Cell Therapy Laboratory, Icahn School of Medicine at Mount Sinai

A physician by training who now directs cutting-edge scientific research in oncology.

More
JEF D. BOEKE, Ph.D., D.Sc.
Founding Director, Institute for Systems Genetics at NYU Langone Medical Center

The founding director of The Institute for Systems Genetics at NYU Langone Medical Center.

More
JOHN COFFIN, Ph.D.
American Cancer Society Research Professor, Tufts University School of Medicine

A veteran policy analyst who has helped advise the director of the National Cancer Center’s Center for Cancer Research, among other prominent institutions.

More
MATTHIAS GÖTTE, Ph.D.
Professor, Medical Microbiology and Immunology, University of Alberta

An expert in viral replication who has contributed to the development of novel classes of viral polymerase inhibitors.

More
DANIEL HABER, M.D., Ph.D.
Director, Massachusetts General Hospital Cancer Center

A leading researcher in cancer genetics who has made seminal discoveries on genetic drivers of lung and breast cancer, among other diseases.

More
ARNIE LEVINE, Ph.D.
Professor Emeritus, Simons Center for Systems Biology, Princeton University

A biologist who has helped shape U.S. science priorities and who helped discover the p53 tumor suppressor protein.

More
TOMAS MUSTELIN, MD, D. Med. Sci.
Professor of Medicine and Chief of Rheumatology at the University of Washington

Tomas Mustelin is the Professor of Medicine and Chief of Rheumatology at the University of Washington.

More

Investors